Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) Stock Overview
Explore Dianthus Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
3.9B
P/E Ratio
-383.12
EPS (TTM)
$-4.23
ROE
-0.02%
DNTH Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Dianthus Therapeutics, Inc. (DNTH) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 62.37, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $43.22.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -383.12 and a market capitalization of 3.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.